Biogen Idec (BIIB) reported second-quarter earnings per share of $1.27, well above the year-ago figure of $0.73 and the Zacks Consensus Estimate of $1.08. Revenue increased 11% to $1.2 billion, with Tysabri and Rituxan being the primary growth drivers.

Based on second quarter results and Biogen’s new guidance for 2010, we have raised our earnings estimate for 2010 by 29 cents to $4.73. Key products Avonex and Tysabri continue to contribute significantly to sales and we expect Biogen to maintain its leading position in the multiple sclerosis market. The company is working on building its pipeline through acquisitions and in-licensing deals.

In our opinion, Biogen has the best pipeline in all of biotech, and could be an attractive takeover candidate for pharma companies interested in biologics. Although we remain concerned about an increase in the occurrence of PML in patients using Tysabri, we are upgrading the stock to Outperform based on the second quarter performance and improved outlook for 2010.

Zacks Investment Research

1. (BIIB) Biogen Idec Second Quarter 2010 Earnings PreviewBiogen Idec Inc. (BIIB) is set to announce its second quarter 2010 results on Tuesday,...
2. (BIIB) Biogen Idec and Abbott Laboratories Begin Patient Enrollment in StudyBiogen Idec (BIIB) and Abbott (ABT) recently announced that they have started enrolling patients for...
3. (BIIB) Biogen Idec Beats Expectations and Guides HigherBiogen Idec Inc. (BIIB) reported fourth quarter earnings per share of $1.18, beating the Zacks...
4. (BIIB) Biogen Idec Announces New PML Cases In Patients Taking Their Multiple Sclerosis Drug TysabriBiogen Idec Inc. (BIIB) recently announced that 4 more cases of progressive multifocal leukeoencephalopathy (PML),...
5. (BIIB) Court Rules in Favor of Biogen IdecBiogen Idec (BIIB) received good news yesterday in the form of a favorable court ruling...
6. (BIIB) Biogen Idec – third-quarter results that included a 64% spike in earningsBiogen Idec Inc. (BIIB) shares continue to climb as the company’s next earnings announcement quickly...

Search Posts by Tag: BIIB | Biogen Idec Inc | Biotechnology | Healthcare

RSS Feeds by Tag: BIIB | Biogen Idec Inc | Biotechnology | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author